We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
Read MoreHide Full Article
Shares of Global Blood Therapeutics have surged 98.7% in the past year compared with the industry’s growth of 8.7%.
In November 2019, the FDA approved its lead candidate voxelotor as an oral, once-daily treatment for SCD in patients aged 12 years or above. The drug will be marketed by the trade name Oxbryta. The approval comes almost three months ahead of the scheduled action date of Feb 26, 2020. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.
Following this, Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD.
The company has another pipeline candidate, inclacumab, a novel fully human monoclonal antibody against P-selectin, in its portfolio. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG (RHHBY - Free Report) .
However, Global Blood has only one approved product in its portfolio. If voxelotor does not do well, the business will be significantly affected, as inclacumab is in the early stages of development.
The company is also battling stiff competition. Novartis’ (NVS - Free Report) drug Adakveo (crizanlizumab) was also approved by the FDA in November 2019 to reduce the frequency of VOCs, or pain crises, in adult and pediatric patients aged 16 years or above with SCD.
Zacks Rank and a Stock to Consider
Global Blood currently has a Zacks Rank #3 (Hold).
Alexion’s earnings per share estimates have increased from $1.59 to $2.03 for 2019 and from $1.22 to $1.34 for 2020 in the past 90 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.” Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
Shares of Global Blood Therapeutics have surged 98.7% in the past year compared with the industry’s growth of 8.7%.
In November 2019, the FDA approved its lead candidate voxelotor as an oral, once-daily treatment for SCD in patients aged 12 years or above. The drug will be marketed by the trade name Oxbryta. The approval comes almost three months ahead of the scheduled action date of Feb 26, 2020. SCD is a chronic, inherited blood disorder that affects hemoglobin levels.
Following this, Oxbryta became the first approved therapy that directly inhibits sickle hemoglobin polymerization, a major cause for SCD.
The company has another pipeline candidate, inclacumab, a novel fully human monoclonal antibody against P-selectin, in its portfolio. The drug is being developed as a treatment for vaso-occlusive crises (“VOC”) in patients with SCD. The company is developing inclacumab with drug giant Roche Holding AG (RHHBY - Free Report) .
However, Global Blood has only one approved product in its portfolio. If voxelotor does not do well, the business will be significantly affected, as inclacumab is in the early stages of development.
The company is also battling stiff competition. Novartis’ (NVS - Free Report) drug Adakveo (crizanlizumab) was also approved by the FDA in November 2019 to reduce the frequency of VOCs, or pain crises, in adult and pediatric patients aged 16 years or above with SCD.
Zacks Rank and a Stock to Consider
Global Blood currently has a Zacks Rank #3 (Hold).
Another better-ranked stock in the biotech sector is Alexion Pharmaceuticals Inc. sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alexion’s earnings per share estimates have increased from $1.59 to $2.03 for 2019 and from $1.22 to $1.34 for 2020 in the past 90 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.” Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>